Birgitta Abrahamsson

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Cardiovascular Risk Factors

Glycemic Control

Top Venues

Nature metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)